Navigation Links
Silence Therapeutics Announces Issuance of Japanese Patent for Screening Therapeutics Against Key Pathway Associated with Cancer and Other Diseases
Date:9/16/2011

s.

The Company's lead internal drug candidate is Atu027, a liposomal formulation in clinical development for systemic cancer indications and one of the most clinically advanced RNAi therapeutic candidates in the area of oncology. Atu027 incorporates two of the Company's technologies, AtuRNAi and AtuPLEX. Silence is currently conducting an open-label, single-centre, dose-escalation Phase I study with Atu027 in patients with advanced solid tumors involving single, as well as repeated, intravenous administration. Encouraging interim data were presented at the American Society of Clinical Oncology Annual Meeting in June 2011. The results of this study are expected in the first half of 2012.

The Company's RNAi therapeutic platform has received key validation through multiple partnerships with pharmaceutical companies including AstraZeneca, Dainippon Sumitomo, Pfizer/Quark, and Novartis/Quark. Silence is actively pursuing the establishment of additional partnerships. Silence Therapeutics has operations in both Berlin and London.

Forward-Looking Statements

This press release includes forward-looking statements that are subject to risks, uncertainties and other factors. These risks and uncertainties could cause actual results to differ materially from those referred to in the forward-looking statements. All forward-looking statements are based on information currently available to Silence Therapeutics and Silence Therapeutics assumes no obligation to update any such forward-looking statements.

For further information, please contact:

Silence Therapeutics Singer Capital Markets Max Herrmann/Thomas Christely Shaun Dobson/Claes Spång +44(0)20-7491-6520/ +49-30-9489-2800 +44(0)20-32057500 m.herrmann@silence-therapeutics.com shaun.dobson@singercm.com t.christ
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Silence Therapeutics and InteRNA Technologies Sign Collaboration to Develop Novel microRNA Therapeutics
2. Silence Therapeutics Receives Notice of Allowance for New U.S. Patent Covering Novel Small Interfering RNA (siRNA) Delivery Technology
3. Silence Therapeutics Phase I Atu027 Data Accepted for Presentation at the American Society of Clinical Oncology 2011 Annual Meeting
4. Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials
5. Silence Therapeutics Provides Year-end Update
6. Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
7. Silence Therapeutics and AstraZeneca Extend siRNA Development Collaboration
8. Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company
9. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
10. Silence Therapeutics Announces Board Changes
11. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... LONDON and BOSTON , January ... structure-guided drug discovery and development company, is delighted to announce ... has been awarded to Miles Congreve (Vice President ... co-founder) and Malcolm Weir (Chief Executive Officer and ...
(Date:1/22/2015)... (NYSE: RMD ) today announced results for its ... $423.0 million, a 10 percent increase compared to the quarter ... constant currency basis). Net income was $91.2 million, an increase ... 2013. Diluted earnings per share for the quarter were $0.64, ...
(Date:1/22/2015)... 22, 2015 Increasing sophistication among enterprise buyers of ... purchasing in 2015, says Moravia CMO, ... study by market research firm Common Sense Advisory, 15 ... their translation and localization needs. "From a language industry ...
Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2
... 11, 2011 Isis Pharmaceuticals, Inc. (Nasdaq: ... in Isis, Development PipelineWhen: , Wednesday, April 13, 2011 at ... the Internet. Simply log onto our Web site, www.isispharm.com ... unable to participate during the live event, a replay of ...
... Cellceutix Corporation (OTCQB: CTIX), a biopharmaceutical company ... drugs to treat severe medical conditions including ... their recent poster at the 102nd Annual ... Research (AACR)  generated significant interest from major ...
Cached Medicine Technology:Cellceutix Poster Presentation on its p53 Cancer Breakthrough Attracts Wide Interest at 102nd AACR Meeting 2Cellceutix Poster Presentation on its p53 Cancer Breakthrough Attracts Wide Interest at 102nd AACR Meeting 3
(Date:1/22/2015)... IPSWICH, Mass. (PRWEB) January 22, 2015 ... Association (AMA) are expanding their relationship in an effort ... journals around the world. While EBSCO has long made AMA ... as a sales agent for The JAMA Network. ...
(Date:1/22/2015)... is a famous dress online store for wedding dresses and ... collection of wedding dresses , and launches a site-wide women’s ... dress on your big day; the wedding gown is the ... to find the most suitable wedding dress. Now, we are ...
(Date:1/22/2015)... a new blog post explaining the importance of keeping a first ... an auto insurance policy . , Clients who driver safer ... vehicle insurance policies. The safety a vehicle offers from its driver ... this, drivers should always carry a first aid kit in their ...
(Date:1/22/2015)... 2015 State Forestry Institute of Mecklenburg-Vorpommern ... with support from GEOSYSTEMS, a dedicated Hexagon Geospatial and ... leverage Hexagon Geospatial’s ERDAS APOLLO for cataloging, ... as point clouds and documents. This effort will enable ...
(Date:12/26/2014)... 26, 2014 It is said that nothing ... Today, UWDress.com, the famous wedding dress supplier, shows its ... site-wide cocktail gown promotion. , UWDress.com’s navy cocktail gowns ... they come in high fashion styles. Simple dresses in bright ...
Breaking Medicine News(10 mins):Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3Health News:UWDress.com Shows Its New Navy Cocktail Dresses For 2015 2
... Track to Deliver Targeted Synergies Sells Rights to Bystolic(TM) ... To Consider a ... Inc. (NYSE: MYL ),today announced its financial results for the ... its synergy targets for the Merck,Generics acquisition, and announced a number ...
... Offers Unique Formulation of Important Cancer Medication -, ... Inc.,(NYSE: HSP ), the world leader in ... hydrochloride injection in the United,States. The medication is ... U.S. sales of more than $545 million. Irinotecan ...
... board of trustees approved a proposal today to create ... pharmacy program will serve a total of 300 students ... of 2010., The proposal, which was presented to ... two years of research and study conducted by,members of ...
... Feb. 27 Dr. Shawn Hook of Arbor Ridge,Clinic ... of Summit,VetPharm,s "The Great Vectra 3D(TM)" $125,000 Giveaway. Dr. ... will receive $25,000 in,medical equipment for his veterinary clinic. ... in February and March, and a final grand prize,winner ...
... special,needs will benefit from a new program to ... for Children with Special Needs, Inc.,(HSCSN), in collaboration ... lead testing to HSCSN member families with small ... on children under age,two as a pilot., ...
... from Princeton University has devised a new experimental technique that ... the human brainstem, the most primitive area of the brain. ... to inquiries into a region that acts as the staging ... other parts of the brain are at the root of ...
Cached Medicine News:Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 2Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 3Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 4Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 5Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 6Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 7Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 8Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 9Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 10Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 11Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 12Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 13Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 14Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 15Health News:Hospira Launches Generic Irinotecan Injection 2Health News:Hospira Launches Generic Irinotecan Injection 3Health News:Hospira Launches Generic Irinotecan Injection 4Health News:PC Trustees Vote to Start New Pharmacy School in S.C. 2Health News:PC Trustees Vote to Start New Pharmacy School in S.C. 3Health News:Summit VetPharm Announces First Winner in its 'Great Vectra 3D(TM)' $125,000 Giveaway 2Health News:Lead Safe D.C. and HSCSN Bring Lead Poisoning Prevention to The District's Children With Special Needs 2Health News:First look: Princeton researchers peek into deepest recesses of human brain 2Health News:First look: Princeton researchers peek into deepest recesses of human brain 3
Power Supply E865 is ideal for electrophoresis and semi-dry blotting applications. The electrical leads from Hoefer Gel apparatus are fully compatible with this new E865 power supply and there is no ...
... C.B.S.SCIENTIFIC offers four different Series ... EPS-3000-II, the EPS-4000-II, and the EPS-6000-II. ... voltage, constant current, and constant power ... a powerful 300 milliamps maximum current/300 ...
... supply replaces the PowerPac 200. With increased output ... the PowerPac HC drives all high-current applications. The ... blotting with any of Bio-Rad's extensive line of ... cell for large format gels up to 26.5 ...
Agarose L03 is recommended for separations of DNA fragments = 1,000 bp....
Medicine Products: